pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.jpg 144 Bayer Berlin, Germany, August 31, 2010 - The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention... http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/0/6/bayer http://pharmalicensing.com/redirs/news_rss//public/news/view/530731/0/6/bayer Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study Stockholm, SE (August 31, 2010) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully... http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/0/6/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study http://pharmalicensing.com/redirs/news_rss//public/news/view/530750/0/6/rivaroxaban-successfully-demonstrated-non-inferiority-compared-to-standard-of-care-for-the-prevention-of-recurrent-venous-thromboembolism-in-pivotal-phase-3-study YM BioSciences granted Orphan Drug Designation for CYT387 MISSISSAUGA, ON, Aug 10, 2010--JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis- YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced that the Office of Orphan Products... http://pharmalicensing.com/redirs/news_rss//public/news/view/530728/0/6/ym-biosciences-granted-orphan-drug-designation-for-cyt387 http://pharmalicensing.com/redirs/news_rss//public/news/view/530728/0/6/ym-biosciences-granted-orphan-drug-designation-for-cyt387 YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study MISSISSAUGA, ON, Aug 05, 2010--YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo... http://pharmalicensing.com/redirs/news_rss//public/news/view/530727/0/6/ym-biosciences-announces-conclusion-of-phase-i-dose-escalation-and-expansion-of-ongoing-cyt387-phase-i-ii-clinical-study http://pharmalicensing.com/redirs/news_rss//public/news/view/530727/0/6/ym-biosciences-announces-conclusion-of-phase-i-dose-escalation-and-expansion-of-ongoing-cyt387-phase-i-ii-clinical-study Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure PALO ALTO, Calif. & OSAKA, Aug 05, 2010 -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary... http://pharmalicensing.com/redirs/news_rss//public/news/view/530690/0/6/affymax-and-takeda-announce-preliminary-u-s-registration-strategy-for-investigational-drug-hematide-tm-peginesatide-to-treat-anemia-in-chronic-renal-failure http://pharmalicensing.com/redirs/news_rss//public/news/view/530690/0/6/affymax-and-takeda-announce-preliminary-u-s-registration-strategy-for-investigational-drug-hematide-tm-peginesatide-to-treat-anemia-in-chronic-renal-failure The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx Jerusalem, Israel, June 21, 2010 --- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to... http://pharmalicensing.com/redirs/news_rss//public/news/view/530909/0/6/the-gamida-cell-teva-joint-venture-receives-fda-fast-track-designation-for-stemex http://pharmalicensing.com/redirs/news_rss//public/news/view/530909/0/6/the-gamida-cell-teva-joint-venture-receives-fda-fast-track-designation-for-stemex